Trial site
Metabolica Sp. z o.o.
Tarnów, 33-100, PolandEU-13 widening countryNot linked to an institution yet
- 14running trials
- 2closed trials
The trials here
What the 16 trials at this site are about, from their registry records.
- Phase
- Phase 311 trials
- Phase 24 trials
- Phase 1/21 trial
- Status
- Active, not recruiting11 trials
- Recruiting3 trials
- Completed2 trials
- Lead sponsor
- Novo Nordisk A/S3 trials
- Boehringer Ingelheim2 trials
- Hoffmann-La Roche2 trials
- Pfizer2 trials
- Abivax1 trial
- and 6 more
Running trials
Not yet recruiting
AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
NCT07931573· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of CX11 Tablets in Patients with Type 2 Diabetes Mellitus
2025-524514-28-00· Phase 2· Corxel Pharmaceuticals Inc.· Source
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
NCT07400653· Phase 3· Pfizer· Source
Active, not recruiting
A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
NCT07340320· Phase 2· Corxel Pharmaceuticals· Source
Active, not recruiting
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
NCT07311850· Phase 3· Pfizer· Source
Active, not recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
2024-516652-18-00· Phase 3· Amgen Inc.· Source
Recruiting
A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes
NCT07112872· Phase 2· Hoffmann-La Roche· Source
Active, not recruiting
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
NCT07076199· Phase 3· Novo Nordisk A/S· Source
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060· Phase 3· AstraZeneca· Source
Active, not recruiting
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
NCT06845202· Phase 1/2· Alnylam Pharmaceuticals· Source
Active, not recruiting
ABTECT - Maintenance
NCT05535946· Phase 3· Abivax S.A.· Source
Active, not recruiting
Effects of ABX464 during long-term treatment in patients with moderate to severe ulcerative colitis
2023-507974-42-00· Phase 2· Abivax· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error